Trials / Completed
CompletedNCT00245960
Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
A RANDOMIZED, OPEN-LABEL, TWO-PERIOD STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ETANERCEPT ON SKIN AND JOINT DISEASE IN PSORIASIS SUBJECTS WITH PSORIATIC ARTHRITIS
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 752 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study was to compare the efficacy of 2 different Etanercept regimens for the treatment of skin and joint manifestations of psoriatic arthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | etanercept | |
| DRUG | etanercept | |
| DRUG | Placebo |
Timeline
- Start date
- 2005-12-27
- Primary completion
- 2008-03-29
- Completion
- 2008-03-29
- First posted
- 2005-10-28
- Last updated
- 2022-01-31
- Results posted
- 2009-05-27
Locations
120 sites across 26 countries: Argentina, Australia, Austria, Belgium, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Mexico, Netherlands, Poland, Portugal, Saudi Arabia, Serbia and Montenegro, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT00245960. Inclusion in this directory is not an endorsement.